I. A. Wilson

This study identifies a broadly neutralizing antibody that targets a conserved site on beta-coronavirus spike proteins and provides protection against SARS-CoV-2 infection.

The paper examines the serological response to the N-terminal domain (NTD) of SARS-CoV-2, showing it is less cross-reactive with SARS-CoV and less effective as an immunogen compared to the RBD.

The paper examines how mutations at E484 and K417 in SARS-CoV-2 variants affect neutralizing antibodies, showing reduced efficacy against certain antibody families but not others.

This study shows that combining cross-neutralizing antibodies CV38-142 and COVA1-16 enhances neutralization of SARS-CoV-2 and SARS-CoV pseudoviruses.

The paper identifies two public IGHV3-53/3-66 clonotypes with distinct CDR H3 motifs and shows Y58F mutation enhances binding affinity to SARS-CoV-2 RBD.

This study isolates HIV-1 neutralizing antibodies from mice and rabbits immunized with gp41-stabilized trimers and nanoparticles, showing they target different epitopes and elicit Env-dependent breadth.

The paper identifies potent SARS-CoV-2 neutralizing antibodies from a pre-pandemic human antibody library, showing high somatic hypermutation and specific binding to the spike protein.

This study shows that prior exposure to one Sarbecovirus strain biases antibody response to a subsequent, antigenically distinct strain, suggesting antigenic imprinting affects immunity to SARS-CoV-2.

This study identifies a single amino acid mutation that determines the difference in neutralization ability of a cross-reactive antibody between SARS-CoV-2 and SARS-CoV.

The paper develops SARS-CoV-2 vaccine candidates by displaying the receptor-binding domain and a stabilized spike on self-assembling protein nanoparticles, showing enhanced neutralizing antibody and T-cell responses.

The paper identifies IGHV3-53 as a common VH gene for SARS-CoV-2 neutralizing antibodies and determines its structural basis for binding the RBD.

The paper identifies a SARS-CoV-2 antibody that cross-neutralizes SARS-CoV by binding a conserved epitope and relies on avidity for neutralization.

This study identifies an alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 RBD, showing that longer CDR H3 can bind with different angles and interactions.

The paper analyzes eight anti-NANP antibodies from a malaria vaccine trial, linking their structural and biophysical properties to in vivo protection against P. falciparum.

This paper identifies a small-molecule inhibitor of influenza A HA stem fusion using a fluorescence polarization screen and validates its antiviral activity against multiple H1N1 and H5N1 strains.

This study examines cross-reactive antibody responses between SARS-CoV-2 and SARS-CoV, finding common binding but rare neutralization, suggesting non-neutralizing antibodies target conserved epitopes.

Structural study of a cross-reactive SARS antibody reveals a conserved epitope on the SARS-CoV-2 receptor-binding domain.

This study identifies vulnerabilities in coronavirus glycan shields by showing that MERS S protein has under-processed oligomannose-type glycan clusters, unlike SARS and HKU1 CoVs, and that these glycans do not form an effective shield against antibodies.

This study maps antibody responses to HIV-1 envelope trimers in non-human primates, identifying strain-specific and conserved epitopes recognized by vaccine-induced antibodies.

This study characterizes a monoclonal antibody against the N-terminal domain of PfCSP, finding it has high affinity but lacks functional inhibitory activity against sporozoites.

The paper evaluates genetic barriers to resistance against broadly neutralizing antibodies targeting the stem region of influenza H3 and H1 hemagglutinins, finding H3 has lower resistance barriers.

This study presents methods to incorporate full-length HIV-1 Env into lipid assemblies for structural analysis, revealing the quaternary epitope of an MPER antibody and Env tilting during neutralization.

This study shows that immunization with B41 and BG505 SOSIP trimer immunogens in rabbits induces distinct autologous neutralizing antibody lineages targeting overlapping glycan hole epitopes, but broadening reactivity remains challenging.

This paper presents an HCV vaccine strategy using redesigned E2 cores displayed on nanoparticles to elicit broadly neutralizing B-cell responses.

The paper describes the structure of a chimpanzee SIV Env trimer and shows it induces HIV V2-specific neutralizing antibodies in mice.

This study shows that high serum neutralizing antibody titers from Env protein vaccination protect rhesus macaques from Tier 2 SHIV challenge, with ~1:500 ID50 titers providing over 90% protection.

The paper identifies a transiently exposed epitope on influenza H7 hemagglutinin that is targeted by a potent neutralizing monoclonal antibody.

This paper demonstrates that gp41ECTO is the main source of HIV-1 envelope metastability and shows that stabilizing it improves nanoparticle assembly and induces more effective tier 2 neutralizing antibodies.

The paper presents a cryo-EM structure of Plasmodium falciparum CSP with vaccine-elicited antibodies, revealing a spiral conformation stabilized by inter-antibody contacts.